Please login to the form below
Olumiant
This page shows the latest Olumiant news and features for those working in and with pharma, biotech and healthcare.
NICE publishes draft guidance recommending three COVID-19 treatments
The treatments recommended by NICE are Roche’s RoActemra (tocilizumab) and Eli Lilly’s Olumiant (baricitinib), both indicated for use in a hospitalised setting in patients requiring supplemental oxygen, as well
Latest news
-
Sobi’s Kineret granted FDA Emergency Use Authorisation for COVID-19 related pneumonia
Eli Lilly and Incyte’s Olumiant (baricitinib) was also approved for emergency use in the US in May 2022, making it the first FDA-approved Janus kinase inhibitor for the treatment
-
EMA issues new guidance to limit use of JAK inhibitors for chronic inflammatory disorders
This included final results from a clinical trial of Xeljanz (tofacitinib), as well as preliminary findings from an observational study involving Olumiant (baricitinib). ... This includes Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib
-
Eli Lilly to make bebtelovimab commercially available to US states from August
In May, Eli Lilly and Incyte were granted FDA approval for their COVID-19 therapy, Olumiant (baricitinib), for the treatment of hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical
-
Eli Lilly to supply US government with 150,000 additional doses of bebtelovimab
In May, Eli Lilly and Incyte were granted FDA approval for their COVID-19 therapy Olumiant (baricitinib) for the treatment of hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical
-
Eli Lilly and Incyte's Olumiant receives FDA approval for alopecia
The double-blind, placebo-controlled trials enrolled 1, 200 patients with severe AA and were randomised to receive a once-daily dose of Olumiant 2mg, Olumiant 4mg or placebo. ... Eli Lilly anticipates that regulatory decisions will be made for Olumiant
More from news
Approximately 10 fully matching, plus 36 partially matching documents found.
Latest Intelligence
-
NICE – but not enough
Olumiant launched in 2017 and received positive recommendations from NICE and SMC in the middle of Q3 that same year. ... Today – more than three years after its NICE TA – Olumiant is finally approaching full implementation.
-
Drug launches to watch in 2019
Lilly’s already-approved Olumiant (baricitinib) and Pfizer’s PF-04965842 are rivals for Abbvie’s upadacitinib, but Gilead and Galapagos’ filgotinib (an AbbVie cast-off) now looks like the biggest
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Webcast: Navigating new frontiers: Ways to find space in the future RA market
In partnership with pharmaphorum. Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely
-
Live webinar: Navigating new frontiers: Ways to find space in the future RA market
Although there are only two drugs in this class available in the region – Eli Lilly’s Olumiant (baricitinib) and Pfizer’s Xeljanz (tofacitinib) – this is not likely to be the case
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- EU outlines measures to mitigate antibiotic shortage across Europe
- Europe’s cancer community publishes new report on transforming patient care
- Meeting healthcare’s rising challenges
- Diversifying Healthcare AI with Federated Learning
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Tidepool’s automated insulin dosing app for type 1 diabetes gets FDA approval
- UK to introduce new regulatory framework for point of care manufacturing
- Navigating the patient experience to improve retention of clinical trial participants
- Europe’s cancer community publishes new report on transforming patient care
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- EU to revise pharmaceuticals law amid antibiotic shortages
- Locus Biosciences announces first patient treated in urinary tract infection trial
- Why everyone in pharma is bending over backwards to be agile
PMHub
Six Degrees Medical Consulting
For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
